These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 9102172

  • 21. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
    Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ.
    Circulation; 1994 Oct; 90(4):1757-64. PubMed ID: 7923659
    [Abstract] [Full Text] [Related]

  • 22. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
    Lele M, Sajid M, Wajih N, Stouffer GA.
    Circulation; 2001 Jul 31; 104(5):582-7. PubMed ID: 11479257
    [Abstract] [Full Text] [Related]

  • 23. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction.
    Neumann FJ, Zohlnhöfer D, Fakhoury L, Ott I, Gawaz M, Schömig A.
    J Am Coll Cardiol; 1999 Nov 01; 34(5):1420-6. PubMed ID: 10551687
    [Abstract] [Full Text] [Related]

  • 24. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.
    Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE.
    Blood; 1996 Aug 01; 88(3):907-14. PubMed ID: 8704248
    [Abstract] [Full Text] [Related]

  • 25. Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen.
    Chavakis T, Kanse SM, Pixley RA, May AE, Isordia-Salas I, Colman RW, Preissner KT.
    FASEB J; 2001 Nov 01; 15(13):2365-76. PubMed ID: 11689462
    [Abstract] [Full Text] [Related]

  • 26. A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1).
    Altieri DC, Edgington TS.
    J Immunol; 1988 Oct 15; 141(8):2656-60. PubMed ID: 3049815
    [Abstract] [Full Text] [Related]

  • 27. The structural motif glycine 190-valine 202 of the fibrinogen gamma chain interacts with CD11b/CD18 integrin (alpha M beta 2, Mac-1) and promotes leukocyte adhesion.
    Altieri DC, Plescia J, Plow EF.
    J Biol Chem; 1993 Jan 25; 268(3):1847-53. PubMed ID: 8093615
    [Abstract] [Full Text] [Related]

  • 28. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
    Suzuki K, Sato K, Kamohara M, Kaku S, Kawasaki T, Yano S, Iizumi Y.
    Biol Pharm Bull; 2002 Aug 25; 25(8):1006-12. PubMed ID: 12186399
    [Abstract] [Full Text] [Related]

  • 29. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity.
    Barnard MR, Linden MD, Frelinger AL, Li Y, Fox ML, Furman MI, Michelson AD.
    J Thromb Haemost; 2005 Nov 25; 3(11):2563-70. PubMed ID: 16241954
    [Abstract] [Full Text] [Related]

  • 30. Monocytic cell adhesion to intact and plasmin-modified fibrinogen: possible involvement of Mac-1 (CD11b/CD18) and ICAM-1 (CD54).
    Arefieva TL, Krasnikova TL.
    J Cell Physiol; 2001 Sep 25; 188(3):403-9. PubMed ID: 11473367
    [Abstract] [Full Text] [Related]

  • 31. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ, Satler LF.
    J Invasive Cardiol; 1994 Sep 25; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [Abstract] [Full Text] [Related]

  • 32. New antiplatelet agents: platelet GPIIb/IIIa antagonists.
    Coller BS, Anderson K, Weisman HF.
    Thromb Haemost; 1995 Jul 25; 74(1):302-8. PubMed ID: 8578476
    [Abstract] [Full Text] [Related]

  • 33. AlphaMbeta2 (CD11b/CD18, Mac-1) integrin activation by a unique monoclonal antibody to alphaM I domain that is divalent cation-sensitive.
    Orchekowski RP, Plescia J, Altieri DC, Bajt ML.
    J Leukoc Biol; 2000 Nov 25; 68(5):641-9. PubMed ID: 11073102
    [Abstract] [Full Text] [Related]

  • 34. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec 25; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 35. P-selectin cross-links PSGL-1 and enhances neutrophil adhesion to fibrinogen and ICAM-1 in a Src kinase-dependent, but GPCR-independent mechanism.
    Xu T, Zhang L, Geng ZH, Wang HB, Wang JT, Chen M, Geng JG.
    Cell Adh Migr; 2007 Dec 25; 1(3):115-23. PubMed ID: 19262138
    [Abstract] [Full Text] [Related]

  • 36. Activation of lymphocyte function-associated molecule-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) mimicked by an antibody directed against CD18.
    Petruzzelli L, Maduzia L, Springer TA.
    J Immunol; 1995 Jul 15; 155(2):854-66. PubMed ID: 7608563
    [Abstract] [Full Text] [Related]

  • 37. Platelet surface IgG in patients receiving infusions of Fab fragments of a chimaeric monoclonal antibody to glycoprotein IIb-IIIa.
    Christopoulos C.
    Clin Exp Immunol; 1994 Oct 15; 98(1):6-11. PubMed ID: 7923885
    [Abstract] [Full Text] [Related]

  • 38. Occupancy of CD11b/CD18 (Mac-1) divalent ion binding site(s) induces leukocyte adhesion.
    Altieri DC.
    J Immunol; 1991 Sep 15; 147(6):1891-8. PubMed ID: 1890307
    [Abstract] [Full Text] [Related]

  • 39. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.
    Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ.
    Am J Cardiol; 1995 Mar 15; 75(8):559-62. PubMed ID: 7887377
    [Abstract] [Full Text] [Related]

  • 40. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
    EPIC Investigators.
    N Engl J Med; 1994 Apr 07; 330(14):956-61. PubMed ID: 8121459
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.